Clinical trial
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
NCT00091611 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00091611 |
|---|---|
| Title | Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer |
| Official title | Phase II Study in Metastatic Renal Cell Cancer Using Cultured, Tumor-Reactive Lymphocytes and Interleukin-2 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kidney Neoplasms |
| Intervention type | Drug |
| Interventions | IL-2 (interleukin-2), OKT3, Cyclophosphamide, Fludarabine, Mesna |
| Enrollment | 3 |
| Start date | Sep 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Sep 13, 2004 |
| Last update posted | Oct 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: